Receptos, Inc., a San Diego, CA-based drug discovery and development company, completed a two-tranche $25m Series A financing.
Investors include ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock.
Receptos utilizes G protein-coupled receptor (GPCR) technology to facilitate information-driven drug design for developing drugs.
The funds will support the company’s sphingosine-1-phosphate receptor 1 (S1P1) clinical candidate through Phase 1 human clinical trials, development of a second Investigational New Drug candidate, as well as the select partnering of the proprietary technology platform for GPCR drug discovery and development.
FinSMEs
23/11/2009